Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology

被引：8
作者：
Kern, Rodrigo [1 ,2 ]
Correa, Stephany Christiane [3 ]
Scandolara, Thalita Basso [1 ,4 ]
da Silva, Janaina Carla [1 ,2 ]
Pires, Bruno Ricardo [5 ,6 ]
Panis, Carolina [1 ,2 ]
机构：
[1] State Univ West Parana, Lab Tumor Biol, BR-85601970 Francisco Beltrao, Parana, Brazil
[2] State Univ West Parana, Postgrad Program Hlth Appl Sci, BR-85601970 Francisco Beltrao, Parana, Brazil
[3] Natl Canc Inst INCA, Ctr Bone Marrow Transplantat, Lab Stem Cells, BR-20230130 Rio De Janeiro, RJ, Brazil
[4] Univ Fed Rio de Janeiro, BR-21941901 Rio De Janeiro, RJ, Brazil
[5] Inst Nacl Canc Jose Alencar Gomes da Silva, BR-20230130 Rio De Janeiro, RJ, Brazil
[6] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
来源：
PERSONALIZED MEDICINE | 2020年 / 17卷 / 05期
关键词：
biomarkers; breast cancer; genomic profile; immune checkpoints inhibitors; multigene arrays; personalized treatment; prognosis; therapy development; tumor biology; RANDOMIZED PHASE-II; INTERNATIONAL EXPERT CONSENSUS; PLACEBO PLUS FULVESTRANT; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DOUBLE-BLIND; CTLA-4; BLOCKADE; INFILTRATING LYMPHOCYTES; POSTMENOPAUSAL WOMEN; TAXANE-ANTHRACYCLINE;
D O I：
10.2217/pme-2020-0070
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Breast cancer treatment has advanced enormously in the last decade. Most of this is due to advances reached in the knowledge regarding tumor biology, mainly in the field of diagnosis and treatment. This review brings information about how the genomics-based information contributed to advances in breast cancer diagnosis and prognosis perspective, as well as presents how tumor biology discoveries fostered the main therapeutic approaches available to treat such patients, based on a personalized point of view.
引用
收藏
页码：399 / 420
页数：22
相关论文
共 165 条
[1]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2]   Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). [J].
Adams, Sylvia ;
Dieras, Veronique ;
Barrios, Carlos H. ;
Winer, Eric P. ;
Schneeweiss, Andreas ;
Iwata, Hiroji ;
Loi, Sherene ;
Patel, Sheetal ;
Henschel, Volkmar ;
Chui, Stephen Y. ;
Rugo, Hope S. ;
Emens, Leisha A. ;
Schmid, Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3]   Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].
Adams, Sylvia ;
Diamond, Jennifer R. ;
Hamilton, Erika ;
Pohlmann, Paula R. ;
Tolaney, Sara M. ;
Chang, Ching-Wei ;
Zhang, Wei ;
Iizuka, Koho ;
Foster, Paul G. ;
Molinero, Luciana ;
Funke, Roel ;
Powderly, John .
JAMA ONCOLOGY, 2019, 5 (03) :334-342
[4]   Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. [J].
Adams, Sylvia ;
Schmid, Peter ;
Rugo, Hope S. ;
Winer, Eric P. ;
Loirat, Delphine ;
Awada, Ahmad ;
Cescon, David W. ;
Iwata, Hiroji ;
Campone, Mario ;
Nanda, Rita ;
Hui, Rina ;
Curigliano, Giuseppe ;
Toppmeyer, Deborah ;
O'Shaughnessy, Joyce ;
Loi, Sherene ;
Paluch-Shimon, Shani ;
Card, Deborah ;
Zhao, Jing ;
Karantza, Vassiliki ;
Cortes, Javier .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[6]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[7]   Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].
Andre, Fabrice ;
Ciruelos, Eva ;
Rubovszky, Gabor ;
Campone, Mario ;
Loibl, Sibylle ;
Rugo, Hope S. ;
Iwata, Hiroji ;
Conte, Pierfranco ;
Mayer, Ingrid A. ;
Kaufman, Bella ;
Yamashita, Toshinari ;
Lu, Yen-Shen ;
Inoue, Kenichi ;
Takahashi, Masato ;
Papai, Zsuzsanna ;
Longin, Anne-Sophie ;
Mills, David ;
Wilke, Celine ;
Hirawat, Samit ;
Juric, Dejan .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940
[8]  
[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043
[9]  
von Minckwitz Gunter, 2017, N Engl J Med, V377, P122, DOI [10.1056/NEJMx170011, 10.1056/NEJMoa1703643]
[10]  
[Anonymous], 2019, J CLIN ONCOL S
12345678910